In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in southern Quebec, Canada

被引：76

作者：

Bourgault, Anne-Marie

Lamothe, Francois

Loo, Vivian G.

Poirier, Louise

机构：

[1] Univ Montreal, Ctr Hosp, Hop St Luc, Dept Microbiol Med & Infectiol, Montreal, PQ H2X 3J4, Canada

[2] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[3] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 10期

关键词：

FIELD GEL-ELECTROPHORESIS; METRONIDAZOLE; EPIDEMIC; DIARRHEA; COLITIS; STRAIN; RISK;

D O I：

10.1128/AAC.00479-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Clostridium difficile isolates from a 2004 outbreak in Quebec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (> 80%) were resistant to ceftriaxone, clarithromycin, gatifiloxacin, and moxifiloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.

引用

页码：3473 / 3475

页数：3

共 17 条

[1]

[Anonymous], M11A6 NCCLS

[2] Prevalence and pathogenicity of Clostridium difficile in hospitalized patients - A french multicenter study [J].

Barbut, F ;

Corthier, G ;

Charpak, Y ;

Cerf, M ;

Monteil, H ;

Fosse, T ;

Trevoux, A ;

DeBarbeyrac, B ;

Boussougant, Y ;

Tigaud, S ;

Tytgat, F ;

Sedallian, A ;

Duborgel, S ;

Collignon, A ;

LeGuern, ME ;

Bernasconi, P ;

Petit, JC .

ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (13) :1449-1454

[3] The new Clostridium difficile -: What does it mean? [J].

Bartlett, JG ;

Perl, TM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2503-2505

[4]

CONTANT C, 1996, DIAGN MICROBIOL INFE, V25, P9

[5] Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains [J].

Fawley, WN ;

Wilcox, MH .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (09) :3546-3547

[6] Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates [J].

Freeman, J ;

Wilcox, MH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (02) :244-246

[7] Metronidazole for Clostridium difficile-associated disease:: Is it okay for mom? [J].

Gerding, DN .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) :1598-1600

[8] Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK [J].

John, R ;

Brazier, JS .

JOURNAL OF HOSPITAL INFECTION, 2005, 61 (01) :11-14

[9] E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid [J].

Leroi, MJ ;

Siarakas, S ;

Gottlieb, T .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (01) :72-74

[10] Clostridium difficile:: a formidable foe [J].

Loo, VG ;

Libman, MD ;

Miller, MA ;

Bourgault, AM ;

Frenette, CH ;

Kelly, M ;

Michaud, S ;

Nguyen, T ;

Poirier, L ;

Vibien, A ;

Horn, R ;

Laflamme, PJ ;

René, P .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (01) :47-48

← 1 2 →